The coms randomized trial of iodine 125 brachytherapy for choroidal melanoma

arms, 5- and 10-year all-cause mortality rates were 19% and 35%, respectively; by 12 years, cumulative all-cause mortality was 43% among patients in the 125 I brachytherapyarmand41%amongthoseintheenucleationarm. Five-, 10-, and 12-year rates of death with histopathologicallyconfirmedmelanomametastasiswere10%,18%, and 21%, respectively, in the 125 I brachytherapy arm and 11%,17%,and17%,respectively,intheenucleationarm. Olderageandlargermaximumbasaltumordiameterwere the primary predictors of time to death from all causes and death with melanoma metastasis. Conclusion:Longer follow-up of patients confirmed the earlier report of no survival differences between patients whose tumors were treated with 125 I brachytherapy and those treated with enucleation.